<DOC>
	<DOCNO>NCT00195767</DOCNO>
	<brief_summary>To determine long-term treatment , 6 month , Depakote ER safe effective treatment bipolar I disorder child adolescent .</brief_summary>
	<brief_title>Evaluate Safety Depakote Extended Release Tablets Treatment Mania Associated With Bipolar Disorder Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Subject subject 's legal representative voluntarily sign date IRBapproved informed assent form IRBapproved inform consent form , respectively , studyspecific procedure test perform . The subject randomize Study M01342 either complete study prematurely discontinue due ineffectiveness . The subject male nonpregnant , nonlactating female . Subject judge general good health base upon result physical examination , vital sign , 12lead electrocardiogram ( ECG ) , laboratory profile ( described Section 5.3.1 ) Exclusion Criteria Subject female , childbearing potential , use effective method birth control ( e.g. , total sexual abstinence contraceptive ) . Subject experience serious adverse event Study M01342 , investigator consider `` possibly '' `` probably relate '' study drug . Subject violent , homicidal , suicidal , opinion investigator , subject significant imminent risk hurt self others . Subject follow abnormal laboratory result last assessment prior Day 1 : Platelet count &lt; /= 100,000/ÂµL ; ALT AST &gt; /= 2 time Upper Limit Normal ( ULN ) The subject take protocol allow medication ADHD stable least 3 month prior Day 1 , expect require dosage adjustment study , , investigator opinion , may exacerbate mood symptom . Subject require treatment take protocolprohibited medication ( see Appendix D ) within 5 elimination half live Day 1 . Subject receive investigational drug , Depakote ER Study M01342 , within 30 day prior Day 1 study . In investigator 's opinion , longterm treatment Depakote ER subject 's mania associate bipolar disorder contraindicate . For reason , subject consider investigator unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Bipolar I Disorder</keyword>
	<keyword>Depakote ER</keyword>
	<keyword>divalproex sodium</keyword>
</DOC>